{"product_id":"evidence-based-pediatric-oncology-isbn-9780470659649","title":"Evidence-Based Pediatric Oncology","description":"\u003cp\u003e\u003cb\u003eThe new and updated edition of the renowned reference for pediatric oncologists\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThis groundbreaking text on the management of childhood cancers covers most tumor types occurring in children and young adults and provides reviews of randomized trials with commentaries on the optimum treatments for childhood cancer.\u003c\/p\u003e \u003cp\u003eUpdated with evidence from the latest published reviews—and even more clinically focused than previous editions— \u003cb\u003eEvidence-Based Pediatric Oncology, Third Edition\u003c\/b\u003e places an emphasis on application of the trial findings. With increased coverage of the area of supportive care for pediatric cancer patients, each chapter opens with an expert commentary on the key clinical issues followed by a summary of trial findings.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEvidence-Based Pediatric Oncology, Third Edition\u003c\/b\u003e:\u003c\/p\u003e \u003cp\u003e• Presents evidence for the best treatment of children and adolescents with cancer\u003c\/p\u003e \u003cp\u003e• Includes commentaries from the world’s leading experts for every topic discussed\u003c\/p\u003e \u003cp\u003e• Is internationally relevant thanks to contributions from the UK, US, Canada and Australia\u003c\/p\u003e \u003cp\u003e• Places greater emphasis on supportive care and features a new extended section on antibiotic and antifungal treatments\u003c\/p\u003e \u003cp\u003eBased on information gathered from randomized trials performed after the release of the Second Edition, readers will find \u003cb\u003eEvidence-Based Pediatric Oncology\u003c\/b\u003e to be an important resource for all those treating young people with cancer.\u003c\/p\u003e \u003cp\u003eList of contributors, vii\u003c\/p\u003e \u003cp\u003ePreface, ix\u003c\/p\u003e \u003cp\u003eList of abbreviations, x\u003c\/p\u003e \u003cp\u003eAbout the companion website, xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: Solid tumors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Rhabdomyosarcoma, 3\u003cbr\u003e\u003ci\u003eKatherine K. Matthay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Meriel Jenney)\u003c\/p\u003e \u003cp\u003e2 Osteosarcoma, 14\u003cbr\u003e\u003ci\u003eKatherine K. Matthay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Maria Michelagnoli)\u003c\/p\u003e \u003cp\u003e3 Ewing sarcoma, 25\u003cbr\u003e\u003ci\u003eKatherine K. Matthay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Steven G. DuBois)\u003c\/p\u003e \u003cp\u003e4 Wilms tumor, 34\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Kathy Pritchard-Jones)\u003c\/p\u003e \u003cp\u003e5 Neuroblastoma, 47\u003cbr\u003e\u003ci\u003eKatherine K. Matthay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Katherine K. Matthay)\u003c\/p\u003e \u003cp\u003e6 Hepatoblastoma, 58\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Penelope Brock)\u003c\/p\u003e \u003cp\u003e7 Malignant germ cell tumors, 65\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Ross Pinkerton)\u003c\/p\u003e \u003cp\u003e8 Medulloblastoma, 69\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Eric Bouffet)\u003c\/p\u003e \u003cp\u003e9 Glioma, 81\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Joann L. Ater)\u003c\/p\u003e \u003cp\u003e10 Non-Hodgkin lymphoma, 88\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Ross Pinkerton)\u003c\/p\u003e \u003cp\u003e11 Hodgkin lymphoma, 105\u003cbr\u003e\u003ci\u003eRoss Pinkerton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Cindy L. Schwartz)\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: Leukemia\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1: Acute myeloid leukemia 12 Acute myeloid leukemia commentary, 119\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRobert J. Arceci\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Remission induction in acute myeloid leukemia, 126\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Acute myeloid leukemia consolidation, 135\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Maintenance treatment in acute myeloid leukemia, 137\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Autologous bone marrow transplantation in acute myeloid leukemia, 141\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Acute myeloid leukemia: miscellaneous, 144\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2: Childhood lymphoblastic leukemia\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 Childhood lymphoblastic leukemia commentary, 146\u003cbr\u003e\u003ci\u003eVaskar Saha\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Remission induction in childhood lymphoblastic leukemia, 154\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Central nervous system-directed therapy in childhood lymphoblastic leukemia, 168\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Maintenance treatment in childhood lymphoblastic leukemia, 180\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Relapsed childhood lymphoblastic leukemia, 198\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Postinduction therapy in adolescents and young adults with acute lymphoblastic leukemia, 204\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Supportive care in pediatric oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Colony-stimulating factors, 209\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Victoria Grandage)\u003c\/p\u003e \u003cp\u003e25 Cardioprotection in pediatric oncology, 230\u003cbr\u003e\u003ci\u003eAnanth Shankar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Gill A. Levitt)\u003c\/p\u003e \u003cp\u003e26 Infections in pediatric and adolescent oncology, 243\u003cbr\u003e\u003ci\u003eAnanth Shankar and Sara Stoneham\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e(Commentary by Julia E. Clark)\u003c\/p\u003e \u003cp\u003eIndex, 269\u003c\/p\u003e  \u003cp\u003eEdited by\u003cbr\u003e \u003cb\u003eRoss Pinkerton, MB, BCh, BaO, MD,\u003c\/b\u003e Executive Director, Division of Oncology, Royal Children’s Hospital, Children’s Health Queensland, Brisbane, QLD, Australia\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnanth Shankar, MD, FRCPCH\u003c\/b\u003e, Consultant in Paediatric and Adolescent Oncology, University College\u003cbr\u003e London Hospitals NHS Foundation Trust, London, UK\u003c\/p\u003e \u003cp\u003e\u003cb\u003eKatherine K. Matthay, BA, MD,\u003c\/b\u003e Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology, Department of Pediatrics, UCSF School of Medicine and UCSF Benioff Children’s Hospital, San Francisco, CA, USA\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eThe new and updated edition of the renowned reference for pediatric oncologists\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThis groundbreaking text on the management of childhood cancers covers most tumor types occurring in children and young adults and provides reviews of randomized trials with commentaries on the optimum treatments for childhood cancer.\u003c\/p\u003e \u003cp\u003eUpdated with evidence from the latest published reviews—and even more clinically focused than previous editions— \u003cb\u003eEvidence-Based Pediatric Oncology, Third Edition\u003c\/b\u003e places an emphasis on application of the trial findings. With increased coverage of the area of supportive care for pediatric cancer patients, each chapter opens with an expert commentary on the key clinical issues followed by a summary of trial findings.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEvidence-Based Pediatric Oncology, Third Edition\u003c\/b\u003e:\u003c\/p\u003e \u003cp\u003e• Presents evidence for the best treatment of children and adolescents with cancer\u003c\/p\u003e \u003cp\u003e• Includes commentaries from the world’s leading experts for every topic discussed\u003c\/p\u003e \u003cp\u003e• Is internationally relevant thanks to contributions from the UK, US, Canada and Australia\u003c\/p\u003e \u003cp\u003e• Places greater emphasis on supportive care and features a new extended section on antibiotic and antifungal treatments\u003c\/p\u003e \u003cp\u003eBased on information gathered from randomized trials performed after the release of the Second Edition, readers will find \u003cb\u003eEvidence-Based Pediatric Oncology\u003c\/b\u003e to be an important resource for all those treating young people with cancer.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989176172773,"sku":"NP9780470659649","price":149.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470659649.jpg?v=1761783098","url":"https:\/\/k12savings.com\/es\/products\/evidence-based-pediatric-oncology-isbn-9780470659649","provider":"K12savings","version":"1.0","type":"link"}